



## Molecular Research of Triple-Negative Breast Cancer

Guest Editors:

### Dr. Anna De Blasio

Department of Biological,  
Chemical and Pharmaceutical  
Sciences and Technologies  
(STEBICEF), Laboratory of  
Biochemistry, University of  
Palermo, Viale delle Scienze, ed.  
16, 90128 Palermo, Italy

### Dr. Daniela Carlisi

Department of Biomedicine,  
Neurosciences and Advanced  
Diagnostics (BIND), Institute of  
Biochemistry, University of  
Palermo, Via del Vespro, 131,  
90127 Palermo, Italy

Deadline for manuscript  
submissions:

**closed (31 May 2024)**

### Message from the Guest Editors

Breast cancer is classified on the basis of histological and molecular variability; a subgroup equally heterogeneous is triple-negative breast cancer (TNBC), which shows lost expression of PR, ER and HER2/NEU receptors and a general molecular expression that confers it a particularly metastatic and invasive nature, drug resistance and poor prognosis. Therefore, several subtypes that actually have no specific molecular targets characterize TNBC and, consequently, a feature that makes it difficult to set a valid therapeutic strategy and so, to date, conventional chemotherapy is the only choice.

The Special Issue aims to collect recent results in this context, as:

- Genetic, epigenetic, transcriptional profiles;
- Description of proteomic features and/or biochemical pathways;
- Identification of cancer stem cells and their cross-talk with microenvironment; metabolic reprogramming;
- Effect induced in vitro/in vivo of any (or combination of) drugs;
- Triple-negative breast cancer immunity and metabolic reprogramming;
- Any evidence useful to suggest and define novel molecular target to challenge the aggressive character of TNBC.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)